nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Proteinuria—Dapsone—leprosy	0.0432	0.0432	CcSEcCtD
Milnacipran—Parkinsonism—Thalidomide—leprosy	0.0427	0.0427	CcSEcCtD
Milnacipran—Protein urine present—Dapsone—leprosy	0.0426	0.0426	CcSEcCtD
Milnacipran—Galactorrhoea—Thalidomide—leprosy	0.0299	0.0299	CcSEcCtD
Milnacipran—Endocrine disorder—Thalidomide—leprosy	0.0234	0.0234	CcSEcCtD
Milnacipran—Proteinuria—Thalidomide—leprosy	0.0221	0.0221	CcSEcCtD
Milnacipran—Protein urine present—Thalidomide—leprosy	0.0218	0.0218	CcSEcCtD
Milnacipran—Hypercholesterolaemia—Thalidomide—leprosy	0.0205	0.0205	CcSEcCtD
Milnacipran—Dry eye—Thalidomide—leprosy	0.0179	0.0179	CcSEcCtD
Milnacipran—Vision blurred—Dapsone—leprosy	0.0156	0.0156	CcSEcCtD
Milnacipran—Renal failure acute—Thalidomide—leprosy	0.0153	0.0153	CcSEcCtD
Milnacipran—Libido decreased—Thalidomide—leprosy	0.0152	0.0152	CcSEcCtD
Milnacipran—Hyponatraemia—Thalidomide—leprosy	0.0141	0.0141	CcSEcCtD
Milnacipran—Disturbance in sexual arousal—Thalidomide—leprosy	0.014	0.014	CcSEcCtD
Milnacipran—Migraine—Thalidomide—leprosy	0.0139	0.0139	CcSEcCtD
Milnacipran—Tachycardia—Dapsone—leprosy	0.0132	0.0132	CcSEcCtD
Milnacipran—Liver function test abnormal—Thalidomide—leprosy	0.013	0.013	CcSEcCtD
Milnacipran—Dry skin—Thalidomide—leprosy	0.0129	0.0129	CcSEcCtD
Milnacipran—Breast disorder—Thalidomide—leprosy	0.0127	0.0127	CcSEcCtD
Milnacipran—Abdominal distension—Thalidomide—leprosy	0.0123	0.0123	CcSEcCtD
Milnacipran—Insomnia—Dapsone—leprosy	0.0122	0.0122	CcSEcCtD
Milnacipran—Angina pectoris—Thalidomide—leprosy	0.0119	0.0119	CcSEcCtD
Milnacipran—Neutropenia—Thalidomide—leprosy	0.0114	0.0114	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Milnacipran—Pollakiuria—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Milnacipran—Erectile dysfunction—Thalidomide—leprosy	0.0112	0.0112	CcSEcCtD
Milnacipran—Gastrointestinal pain—Dapsone—leprosy	0.0111	0.0111	CcSEcCtD
Milnacipran—Weight decreased—Thalidomide—leprosy	0.011	0.011	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Thalidomide—leprosy	0.0108	0.0108	CcSEcCtD
Milnacipran—Abdominal pain—Dapsone—leprosy	0.0107	0.0107	CcSEcCtD
Milnacipran—Body temperature increased—Dapsone—leprosy	0.0107	0.0107	CcSEcCtD
Milnacipran—Haematuria—Thalidomide—leprosy	0.0104	0.0104	CcSEcCtD
Milnacipran—Hepatitis—Thalidomide—leprosy	0.00975	0.00975	CcSEcCtD
Milnacipran—Hypoaesthesia—Thalidomide—leprosy	0.0097	0.0097	CcSEcCtD
Milnacipran—Urinary tract disorder—Thalidomide—leprosy	0.00963	0.00963	CcSEcCtD
Milnacipran—Oedema peripheral—Thalidomide—leprosy	0.0096	0.0096	CcSEcCtD
Milnacipran—Urethral disorder—Thalidomide—leprosy	0.00956	0.00956	CcSEcCtD
Milnacipran—Erythema multiforme—Thalidomide—leprosy	0.00922	0.00922	CcSEcCtD
Milnacipran—Eye disorder—Thalidomide—leprosy	0.00911	0.00911	CcSEcCtD
Milnacipran—Cardiac disorder—Thalidomide—leprosy	0.00905	0.00905	CcSEcCtD
Milnacipran—Angiopathy—Thalidomide—leprosy	0.00885	0.00885	CcSEcCtD
Milnacipran—Mediastinal disorder—Thalidomide—leprosy	0.00879	0.00879	CcSEcCtD
Milnacipran—Chills—Thalidomide—leprosy	0.00875	0.00875	CcSEcCtD
Milnacipran—Vomiting—Dapsone—leprosy	0.0086	0.0086	CcSEcCtD
Milnacipran—Mental disorder—Thalidomide—leprosy	0.00854	0.00854	CcSEcCtD
Milnacipran—Malnutrition—Thalidomide—leprosy	0.00849	0.00849	CcSEcCtD
Milnacipran—Headache—Dapsone—leprosy	0.00848	0.00848	CcSEcCtD
Milnacipran—Flatulence—Thalidomide—leprosy	0.00836	0.00836	CcSEcCtD
Milnacipran—Tension—Thalidomide—leprosy	0.00833	0.00833	CcSEcCtD
Milnacipran—Dysgeusia—Thalidomide—leprosy	0.00831	0.00831	CcSEcCtD
Milnacipran—Nausea—Dapsone—leprosy	0.00804	0.00804	CcSEcCtD
Milnacipran—Vision blurred—Thalidomide—leprosy	0.008	0.008	CcSEcCtD
Milnacipran—Tremor—Thalidomide—leprosy	0.00795	0.00795	CcSEcCtD
Milnacipran—Agitation—Thalidomide—leprosy	0.0078	0.0078	CcSEcCtD
Milnacipran—Syncope—Thalidomide—leprosy	0.00761	0.00761	CcSEcCtD
Milnacipran—Leukopenia—Thalidomide—leprosy	0.0076	0.0076	CcSEcCtD
Milnacipran—Palpitations—Thalidomide—leprosy	0.0075	0.0075	CcSEcCtD
Milnacipran—Loss of consciousness—Thalidomide—leprosy	0.00746	0.00746	CcSEcCtD
Milnacipran—Convulsion—Thalidomide—leprosy	0.00735	0.00735	CcSEcCtD
Milnacipran—Hypertension—Thalidomide—leprosy	0.00733	0.00733	CcSEcCtD
Milnacipran—Chest pain—Thalidomide—leprosy	0.00723	0.00723	CcSEcCtD
Milnacipran—Anxiety—Thalidomide—leprosy	0.0072	0.0072	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00718	0.00718	CcSEcCtD
Milnacipran—Dry mouth—Thalidomide—leprosy	0.00707	0.00707	CcSEcCtD
Milnacipran—Infection—Thalidomide—leprosy	0.00688	0.00688	CcSEcCtD
Milnacipran—Shock—Thalidomide—leprosy	0.00681	0.00681	CcSEcCtD
Milnacipran—Nervous system disorder—Thalidomide—leprosy	0.00679	0.00679	CcSEcCtD
Milnacipran—Thrombocytopenia—Thalidomide—leprosy	0.00678	0.00678	CcSEcCtD
Milnacipran—Tachycardia—Thalidomide—leprosy	0.00676	0.00676	CcSEcCtD
Milnacipran—Skin disorder—Thalidomide—leprosy	0.00673	0.00673	CcSEcCtD
Milnacipran—Hyperhidrosis—Thalidomide—leprosy	0.0067	0.0067	CcSEcCtD
Milnacipran—Anorexia—Thalidomide—leprosy	0.0066	0.0066	CcSEcCtD
Milnacipran—Hypotension—Thalidomide—leprosy	0.00647	0.00647	CcSEcCtD
Milnacipran—Insomnia—Thalidomide—leprosy	0.00626	0.00626	CcSEcCtD
Milnacipran—Paraesthesia—Thalidomide—leprosy	0.00622	0.00622	CcSEcCtD
Milnacipran—Dyspnoea—Thalidomide—leprosy	0.00617	0.00617	CcSEcCtD
Milnacipran—Somnolence—Thalidomide—leprosy	0.00616	0.00616	CcSEcCtD
Milnacipran—Dyspepsia—Thalidomide—leprosy	0.0061	0.0061	CcSEcCtD
Milnacipran—Decreased appetite—Thalidomide—leprosy	0.00602	0.00602	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Thalidomide—leprosy	0.00598	0.00598	CcSEcCtD
Milnacipran—Fatigue—Thalidomide—leprosy	0.00597	0.00597	CcSEcCtD
Milnacipran—Constipation—Thalidomide—leprosy	0.00592	0.00592	CcSEcCtD
Milnacipran—Gastrointestinal pain—Thalidomide—leprosy	0.00566	0.00566	CcSEcCtD
Milnacipran—Urticaria—Thalidomide—leprosy	0.0055	0.0055	CcSEcCtD
Milnacipran—Abdominal pain—Thalidomide—leprosy	0.00548	0.00548	CcSEcCtD
Milnacipran—Body temperature increased—Thalidomide—leprosy	0.00548	0.00548	CcSEcCtD
Milnacipran—Hypersensitivity—Thalidomide—leprosy	0.0051	0.0051	CcSEcCtD
Milnacipran—Asthenia—Thalidomide—leprosy	0.00497	0.00497	CcSEcCtD
Milnacipran—Pruritus—Thalidomide—leprosy	0.0049	0.0049	CcSEcCtD
Milnacipran—Diarrhoea—Thalidomide—leprosy	0.00474	0.00474	CcSEcCtD
Milnacipran—Dizziness—Thalidomide—leprosy	0.00458	0.00458	CcSEcCtD
Milnacipran—Vomiting—Thalidomide—leprosy	0.0044	0.0044	CcSEcCtD
Milnacipran—Rash—Thalidomide—leprosy	0.00437	0.00437	CcSEcCtD
Milnacipran—Dermatitis—Thalidomide—leprosy	0.00436	0.00436	CcSEcCtD
Milnacipran—Headache—Thalidomide—leprosy	0.00434	0.00434	CcSEcCtD
Milnacipran—Nausea—Thalidomide—leprosy	0.00411	0.00411	CcSEcCtD
